期刊导航

论文摘要

复杂核型急性早幼粒细胞白血病治疗过程中并发维甲酸综合征一例

Acute promyelocytic leukemia with complex karyotype complicated by retinoic acid syndrome during treatment: one case report

作者:

Author:

收稿日期:2019-09-01          年卷(期)页码:2020,43(01):57-61

期刊名称:国际输血及血液学杂志

Journal Name:International Journal of Blood Transfusion and Hematology

关键字:白血病,早幼粒细胞,急性,维甲酸,砷剂,维甲酸综合征,PML-RARα融合基因,全反式维甲酸,三氧化二砷,地塞米松,回顾性研究

Key words:Leukemia, promyelocytic, acute|Tretinoin|Arsenicals|Acute promyelocytic leukemia|Retinoic acid syndrome|PML-RAR;ATRA|ATO|Dexamethasone|Retrospective studies

基金项目:

中文摘要

英文摘要

ObjectiveTo explore the treatment of acute promyelocytic leukemia (APL), and the management of retinoic acid syndrome (RAS) during treatment of APL.

MethodsOn December 28, 2018, one case of APL patient with complex karyotype complicated by RAS who was admitted to the Hematological Disease Center of Lanzhou General Hospital, was selected as the subject. By retrospective analysis, the clinical data of this patient were collected, and the clinical manifestations, diagnosis and treatment process were analyzed. Induction chemotherapy of all-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) was used to treat APL: ATRA 20 mg/time, twice a day, oral, d1-28; ATO 10 mL/d, intravenous injection, d1-14. The RAS treatment regimen was to reduce or discontinue ATRA or ATO, and intravenous injected dexamethasone 10 mg/time, twice a day as soon as possible until hypoxemia is relieved. When patient′s white blood cell count (WBC)>10×109/L and continuously elevated, anthracycline or cytarabine was administrated as appropriate. The procedure followed in this study were in accordance with the requirements of theWorld Medical Association Declaration of Helsinkirevised in 2013. And this patient signed the informed consents for clinical trials.

ResultsOn January 1, 2019, the patient was diagnosed as APL, with PML-RARα (Bcr1 type) positive, complex karyotype and intermediate risk group, based on complete results of relevant laboratory and auxiliary examination. This patient achieved good efficacy after treatment of ATRA+ ATO regimen. After treatment with ATRA, the patient presented fever, respiratory failure, pleural effusion, and increased WBC, etc.. Then RAS was considered. After treatment with dexamethasone, pirarubicin and symptomatic treatment, the patient′s clinical symptoms of RAS were significantly improved. As of February 2019, the patient was generally in good condition and was currently being followed up regularly.

ConclusionsATRA+ ATO regimen has a good efficacy in treatment of APL. When RAS appears during the treatment, glucocorticoids and corresponding treatment should be actively used. Since only one patient was retrospectively analyzed in this study, the exact efficacy of APL and RAS needs further verification by expanding the study sample size.

上一条:血友病B合并凝血因子FⅨ抑制物一例

关闭

Copyright © 2020四川大学期刊社 版权所有.

地址:成都市一环路南一段24号

邮编:610065